MOG Antibody-Induced CNS Demyelination: from Specificity to Function

A11

IgG antibodies (Abs) specific for central nervous system (CNS) antigens such as myelin oligoden-drocytes glycoprotein (MOG) are considered crucial effector molecules in some patients with mul-tiple sclerosis (MS) and related diseases. In the proposed project, we will characterize structural requirements for immune recognition of human MOG and determine IgG-Fc biophysical profiles and effector functions linked to in vivo pathogenicity of human MOG-Abs. In detail, these are our reseach questions:

    1. Do patients with circulating MOG-specific B cells particularly benefit from B cell depletion therapy?
    2. What are the structural requirements for immune recognition of human MOG?
    3. What are the Fc biophysical profiles and effector functions of human MOG-Abs?
    4. How do human MOG-Abs act pathogenetic in vivo?


Meyer et al. J. Immunol. 2013
Principal Investigators:

Prof. Dr. med. Edgard Meinl
Institut für Klinische Neuroimmunologie
LMU München
edgar.meinl@med.uni-muenchen.de

Univ.-Prof. Dr. med. Jan Lünemann
Klinik für Neurologie mit Institut für Translationale Neurologie
Münster
jan.luenemann@ukmuenster.de

News

Tue, 14/12/2021
Save the date: 2nd Inflammation & Imaging Symposium
Münster. Save the date: 12-14 September 2022! We cordially invite you to join this international symposium, jointly organized by the research networks CRC 1450, CRC 1009, CRC 1348, CRU 342, CRC/TR 128 and the Cells in Motion Interfaculty Centre at the University of Münster. At the same time, we will officially open the new research […]...more
Mon, 09/08/2021
Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity
A close interaction between gut immune responses and distant organ-specific autoimmunity including the CNS in multiple sclerosis has been established in recent years. This so-called gut-CNS axis can be shaped by dietary factors, either directly or via indirect modulation of the gut microbiome and its metabolites. Here, SFB 128 PI Luisa Klotz and colleagues report […]...more
Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more